Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.

Milluzzo A, Oteri V, Manuella L, Pulvirenti A, Frittitta L

International journal of obesity (2005)29 Aug 2026

PMID42668312DOI10.1038/s41366-026-02189-xPepBankPUB-42668312

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced percentage body weight from baseline more than placebo across nine trials.
In plain wordsIn adults with overweight or obesity without diabetes, semaglutide injections reduced body weight more than placebo.
Peptide
Semaglutide
Outcome
DecreasePercentage body weight change from baseline
Study
n = 6,239
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Mean difference in body weight
−12.04%
semaglutide vs placebo
Source sentences
Summary
Across nine trials including 6 239 participants, subcutaneous semaglutide significantly reduced percentage body weight from baseline (mean difference [MD] -12.04%, 95% CI -13.08 to -11.00)
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials comparing subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes were identified through systematic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov.
Report a problemFND-4266831201
02HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced waist circumference more than placebo across nine trials.
In plain wordsIn adults with overweight or obesity without diabetes, semaglutide injections reduced waist size more than placebo.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference
Study
n = 6,239
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Mean difference in waist circumference
−9.36 cm
semaglutide vs placebo
Source sentences
Summary
waist circumference (MD -9.36 cm, 95% CI -10.27 to -8.45)
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials comparing subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes were identified through systematic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov.
Report a problemFND-4266831202
03HumanSystematic reviewEfficacy outcome
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced CRP more than placebo across nine trials.
In plain wordsIn adults with overweight or obesity without diabetes, semaglutide injections lowered the inflammation marker CRP more than placebo.
Peptide
Semaglutide
Outcome
DecreaseC-reactive protein
Study
n = 6,239
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Mean difference in CRP
−40.9%
semaglutide vs placebo
Source sentences
Summary
and CRP (MD -40.90%, 95% CI -46.37 to -35.42) versus placebo (all p < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials comparing subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes were identified through systematic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov.
Report a problemFND-4266831203
04HumanSystematic reviewSafety outcome
In adults with overweight or obesity without diabetes, the risk of serious adverse events did not differ significantly between subcutaneous semaglutide and placebo.
In plain wordsIn adults with overweight or obesity without diabetes, semaglutide injections did not cause significantly more or fewer serious side effects than placebo.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n = 6,239
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
RR
1.12 ratio
serious adverse events
Source sentences
Summary
The risk of SAEs did not differ significantly between semaglutide and placebo (risk ratio [RR] 1.12, 95% CI 0.76 to 1.65; p = 0.55).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials comparing subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes were identified through systematic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov.
Report a problemFND-4266831204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.